dovato
Generic: dolutegravir sodium and lamivudine
Labeler: viiv healthcare companyDrug Facts
Product Profile
Brand Name
dovato
Generic Name
dolutegravir sodium and lamivudine
Labeler
viiv healthcare company
Dosage Form
TABLET, FILM COATED
Routes
Active Ingredients
dolutegravir sodium 50 mg/1, lamivudine 300 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
49702-246
Product ID
49702-246_9b88da25-ebce-49ae-8c8a-dcee6f465957
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA211994
Listing Expiration
2027-12-31
Marketing Start
2019-04-08
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
49702246
Hyphenated Format
49702-246
Supplemental Identifiers
RxCUI
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
dovato (source: ndc)
Generic Name
dolutegravir sodium and lamivudine (source: ndc)
Application Number
NDA211994 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 50 mg/1
- 300 mg/1
Packaging
- 30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13)
- 1 BLISTER PACK in 1 CARTON (49702-246-33) / 30 TABLET, FILM COATED in 1 BLISTER PACK
- 1 BLISTER PACK in 1 CARTON (49702-246-62) / 14 TABLET, FILM COATED in 1 BLISTER PACK
Packages (3)
Ingredients (2)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "9b88da25-ebce-49ae-8c8a-dcee6f465957", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "unii": ["1Q1V9V5WYQ", "2T8Q726O95"], "rxcui": ["2122519", "2122526"], "spl_set_id": ["68e45422-43ed-4cfb-9356-fae88d14a53a"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["ViiV Healthcare Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13)", "package_ndc": "49702-246-13", "marketing_start_date": "20190408"}, {"sample": false, "description": "1 BLISTER PACK in 1 CARTON (49702-246-33) / 30 TABLET, FILM COATED in 1 BLISTER PACK", "package_ndc": "49702-246-33", "marketing_start_date": "20240101"}, {"sample": false, "description": "1 BLISTER PACK in 1 CARTON (49702-246-62) / 14 TABLET, FILM COATED in 1 BLISTER PACK", "package_ndc": "49702-246-62", "marketing_start_date": "20240101"}], "brand_name": "Dovato", "product_id": "49702-246_9b88da25-ebce-49ae-8c8a-dcee6f465957", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["HIV Integrase Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "product_ndc": "49702-246", "generic_name": "dolutegravir sodium and lamivudine", "labeler_name": "ViiV Healthcare Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Dovato", "active_ingredients": [{"name": "DOLUTEGRAVIR SODIUM", "strength": "50 mg/1"}, {"name": "LAMIVUDINE", "strength": "300 mg/1"}], "application_number": "NDA211994", "marketing_category": "NDA", "marketing_start_date": "20190408", "listing_expiration_date": "20271231"}